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Background: Kidney disease is associated with an increased total mortality and cardiovascular morbimortality in
the general population and in patients with Type 2 diabetes. The aim of this study is to determine the prevalence
of kidney disease and different types of renal disease in patients with type 2 diabetes (T2DM).
Methods: Cross-sectional study in a random sample of 2,642 T2DM patients cared for in primary care during 2007.
Studied variables: demographic and clinical characteristics, pharmacological treatments and T2DM complications
(diabetic foot, retinopathy, coronary heart disease and stroke). Variables of renal function were defined as follows:
1) Microalbuminuria: albumin excretion rate > 30 mg/g or 3.5 mg/mmol, 2) Macroalbuminuria: albumin excretion
rate > 300 mg/g or 35 mg/mmol, 3) Kidney disease (KD): glomerular filtration rate according to Modification of
Diet in Renal Disease < 60 ml/min/1.73 m2 and/or the presence of albuminuria, 4) Renal impairment (RI): glomerular
filtration rate < 60 ml/min/1.73 m2, 5) Nonalbuminuric RI: glomerular filtration rate < 60 ml/min/1.73 m2 without
albuminuria and, 5) Diabetic nephropathy (DN): macroalbuminuria or microalbuminuria plus diabetic retinopathy.
Results: The prevalence of different types of renal disease in patients was: 34.1% KD, 22.9% RI, 19.5% albuminuria
and 16.4% diabetic nephropathy (DN). The prevalence of albuminuria without RI (13.5%) and nonalbuminuric RI
(14.7%) was similar. After adjusting per age, BMI, cholesterol, blood pressure and macrovascular disease, RI was
significantly associated with the female gender (OR 2.20; CI 95% 1.86–2.59), microvascular disease (OR 2.14; CI 95%
1.8–2.54) and insulin treatment (OR 1.82; CI 95% 1.39–2.38), and inversely associated with HbA1c (OR 0.85 for every
1% increase; CI 95% 0.80–0.91). Albuminuria without RI was inversely associated with the female gender (OR 0.27;
CI 95% 0.21–0.35), duration of diabetes (OR 0.94 per year; CI 95% 0.91–0.97) and directly associated with HbA1c
(OR 1.19 for every 1% increase; CI 95% 1.09–1.3).
Conclusions: One-third of the sample population in this study has KD. The presence or absence of albuminuria
identifies two subgroups with different characteristics related to gender, the duration of diabetes and metabolic
status of the patient. It is important to determine both albuminuria and GFR estimation to diagnose KD.
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The concept of kidney disease is based on the presence
of albuminuria and/or impaired renal function that lasts
for more than three months [1]. Kidney disease is asso-
ciated with an increased total mortality and cardiovascu-
lar morbimortality in the general population [2] and in
patients with Type 2 diabetes (T2DM) [3]. Patients with
T2DM with renal impairment have an increased mortal-
ity risk, specially a higher risk of cardiovascular (CV)
death, when compared to other diabetic patients without
renal impairment [4]. Moreover, albuminuria predicts an
increased risk of myocardial infarction, stroke, CV death,
total death and heart failure in patients with T2DM in
comparison with non-diabetic patients [5]. However, not
all T2DM patients with renal impairment have albumin-
uria [6]. Therefore, the National Kidney Foundation
(NKF) [1] recommends the determination of plasma
creatinine to estimate glomerular filtration rate (GFR),
because renal impairment and albuminuria are inde-
pendently associated with strokes [7]. The simultaneous
presence of renal impairment and albuminuria is asso-
ciated with an increased risk of CV morbidity, increased
risk of total mortality, and progression of renal disease [8].
During a 15-year follow-up, the United Kingdom Pro-
spective Diabetes (UKPDS) study showed that 5% of the
patients with T2DM had a 2-fold increase in creatinine
levels, 20% had macroalbuminuria defined as a urinary
albumin concentration ≥ 300 mg/l, 40% developed renal
impairment, 45% developed microalbuminuria defined
as a urinary albumin concentration 50–299 mg/l and
75% experienced a CV event [9]. Early detection of kid-
ney disease in patients with diabetes is important be-
cause close monitoring of cardiovascular risk factors,
and specific drugs acting on the renin-angiotensin sys-
tem slow down the progression of renal disease [10].
There have been several reports on the prevalence of
kidney disease and forms of renal disease in patients
with T2DM of Mediterranean countries [11-13]. Only
one study has been conducted in a randomly selected
population sample in Spain [14], and they characterized
renal impairment regardless of albuminuria. The main
objective of this study was to determine the prevalence
of kidney disease in patients with T2DM, forms of renal
disease (renal impairment, albuminuria, renal impair-
ment without albuminuria, nonalbuminuric renal im-
pairment and diabetic nephropathy) and associated
variables in a large sample of patients in primary care.
Methods
Study design and organization The Continuous Quality
Improvement Gedaps program gathered information
from primary care centres on the clinical markers and
health outcomes a sample of patients. A detailed descrip-
tion of the evaluation methodology has been previouslydescribed [15]. During the last evaluation in 2007, several
meetings around Catalonia were conducted to encourage
the involvement in the study regardless of participation in
previous evaluations, and to present changes in the data
entry using a webpage (http://www.redgdps.org/index.php?
idregistro=259).
Health providers were instructed to obtain a random
sample from the medical records of patients with T2DM
with more than six months follow-up from diagnosis. A
total sample of 5 patients multiplied by the number of
basic care units (physician/nurse) with a minimum of 30
patients per centre was required. The exclusion criteria
were as follows: type 1 diabetes mellitus; follow-up ex-
clusively conducted by an endocrinologist; and short life
expectancy (terminal patients or those who received
home care). Only patients with plasma creatinine avail-
able were included for the current study.
Due to the retrospective nature of the study, based only
on clinical records, patients were not required to give writ-
ten informed consent. To assure anonymity data were col-
lected and recorded using two different files: one included
demographic variables and the other one clinical variables
linked by a consecutive record number. The study design
and the GCQI program were presented and approved by
the Consell Assessor de la Diabetes (Advisory Board
on Diabetes) of the Health Departament of the Autono-
mous Government in Catalunya that acted as Institutional
Review Board.
Study population The following demographic and clin-
ical characteristics were compared: age, gender, weight,
height, BMI, blood pressure, HbA1c, creatinine, total
cholesterol, HDL cholesterol, albuminuria, duration of
diabetes (in years), estimated cardiovascular risk according
to the Framingham equation calibrated to the Spanish
population [16] (threshold > 10% at 10 years), antidiabetic
treatment, antihypertensive treatment, lipid-lowering ther-
apy, antiplatelet therapy, and smoking status. Obesity was
considered if the BMI was greater than 30 kg/m2. We
found 1164 type 2 diabetic patients who had no available
albuminuria. Figure 1 shows the samples used to calculate
the prevalence of the different forms of kidney disease.
The following outcomes were considered: diabetic foot
(ulcers and amputations), retinopathy, coronary heart
disease (CHD, including angina), and stroke (including
transient ischemic attack). Two composite variables in-
cluding all microvascular complications (albuminuria
and/or retinopathy) and macrovascular complications
(CHD and/or stroke) were separately created. All col-
lected data included the last value recorded in the med-
ical records during 2007.
NKF [1] defines chronic kidney disease by the persist-
ence of a low GFR and/or albuminuria during a period
of at least three months. In our study, since no previous
measurement of creatinine or albuminuria was available,
 Random sample of patients with T2DM included in the 2007 Gedaps evaluation
(n= 3150)
(n= 2,642)
(n= 1,478)
Type 2 diabetic patients with creatinine available            Prevalence of renal impairment
Type 2 diabetic patients with available urinary albumin excretion rate 
Prevalence of kidney disease according to KDIGO worgroup, nonalbuminuric renal 
impairment and albuminuria alone. 
Figure 1 Flow-chart of study.
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tions had persisted longer than three months. Thus, we
defined kidney disease based and renal impairment
based on a single determination. Serum creatinine was
measured on a multiparameter analyzer (Cobas 711,
Roche Modular System, Indianapolis, IN, USA) by the
Jaffé Method with bichromatic measurements according
to the manufacturer’s specifications. Albuminuria was
measured by inmmunoturbidimetry on a Cobas 400
analyzer (Roche, Indianapolis, IN, USA).
The GFR was calculated using the equation previously
published by the MDRD study group [17]. Variables of
renal function were defined as follow: 1) Microalbuminuria:
Albumin excretion rate (AER) > 30 mg/g (3.5 mg/nmol), 2)
Macroalbuminuria: AER > 300 mg/g (35 mg/nmol), 3) Kid-
ney disease: GFR < 60 ml/min/1.73 m2 and/or the presence
of micro or macroalbuminuria, 4) Renal impairment:
GFR < 60 ml/min/1.73 m2, 5) Nonalbuminuric renal
impairment: GFR < 60 ml/min/1.73 m2 without micro or
macroalbuminuria and, 5) Diabetic nephropathy (DN):
macroalbuminuria or microalbuminuria plus diabetic
retinopathy [18].
Patients with available creatinine and UAER were also
classified according to the recent proposal of KDIGO
workgroup [19].
Statistical analysis Quantitative variables were described
using means and standard deviations. Categorical variables
were summarised using absolute and relative frequencies
(i.e., percentages). Bivariate relationships between categor-
ical variables were tested using non-parametric chi-squared
tests. Bivariate relationships between categorical and quan-
titative variables were assessed using ANOVA tests (one
factor). Descriptive statistics and bivariate inferences wereperformed using the SPSS (v. 15) statistical program. The
multivariate analyses of variables associated with different
types of kidney disease in patients with T2DM were
assessed by means of logistic regressions. The variables for
the adjustment were selected on the basis of significant
bivariate relationships. Response variables were assigned
a value of 1 when the particular type of kidney disease
(i.e., renal impairment, DN and kidney disease) occurred,
and patients without any type of kidney disease were
assigned a value of 0. The estimation of the logistic re-
gressions was performed using the R freeware statistical
package (version 2.11.1).
Results
Sample characteristics
From a total sample of 3150 patients with T2DM
included in the 2007 Gedaps evaluation, we included
2,642 patients who have a plasma creatinine available.
Mean age was 68 years (SD 11.6), and 51.5% of the
patients were men. The average duration of diabetes was
7 years (SD 5.6). The mean HbA1c was 6.84% (SD 1.46),
and 67.6% of patients had an HbA1c value less than or
equal to 7%. The mean blood pressure was 137/
76 mmHg. Table 1 shows the main characteristics of the
population. To rule out a bias attributable to patients
without albuminuria data, we compared a subgroups
with available albuminuria data (1,478 patients), and to
the 1,164 patients not having albuminuria data. Of all
variables compared (age, gender, years of evolution,
HbA1c, systolic blood pressure, diastolic blood pressure
and creatinine), only age showed differences (67.59 vs
68.58; p = 0.03).
Table 1 Characteristics of the sample of patients with type 2 diabetes (n = 2,642)
Total Men Women p value
Age, years; mean (SD) 68.06 (11.60) 66.81 (11.63) 69.31 (11.59) < 0.001
Gender,n (%) 2642 1361 (51.5) 1281(48.5) ns
Years of diabetes duration, mean (SD) 7.05 (5.60) 6.58 (5.06) 7.39 (6.04) <0.001
Diabetes duration 5–10 years, n (%) 803 (30.4) 413 (30.4) 390 (30.5) ns
Diabetes duration > 10 years, n (%) 497 (18.8) 231 (17.0) 266 (20.8) < 0.05
BP, mmHg,mean (SD) 137.23/76.52 (14.60/9.05) 136.98/76.49 (14.68/9.10) 137.08/76.43 (14.71/8.89) ns SBP ns DBP
Hypertension,n (%) 1847 (69.9) 894 (65.6) 953 (74.3) <0.001
BP ≤ 140/90 mmHg,n (%) 1896 (71.7) 976 (71.7) 920 (71.8) ns
BP ≤ 130/80 mmHg,n (%) 915 (34.6) 460 (33.8) 455 (35.5) ns
HbA1c, mean (SD) 6.84 (1.46) 6.83 (1.47) 6.85 (1.44) ns
HbA1c ≤ 7%, n (%) 1786 (67.6) 920 (67.6) 866 (67.6) ns
HbA1c ≤ 8%,n (%) 2319 (87.7) 1182 (86.8) 1137 (88.7) ns
Total cholesterol,mg/dl,mean (SD) 194.33 (38.41) 188.06 (38.45) 201.00 (37.25) <0.001
Non-HDL cholesterol, mg/dl,mean (SD) 144,10 (37.44) 140.63 (37.72) 148.10 (36.65) <0.001
Non-HDL cholesterol < 130 mg/dl, n (%) 1007 (38.1) 592 (43.5) 415 (32.4) <0.001
Non-HDL cholesterol < 160 mg/dl, n (%) (1) 1802 (68.2) 957 (70.3) 845 (66.0) 0.025
Obesity, n (%) 1118 (42.3) 471 (34.6) 647 (50.5 <0.001
Tobacco habit, n (%) 365 (13.8) 299 (22.0) 66 (5.1) <0.001
Creatinine, mg/dl (SD) 1.21 (1.03) 1.30 (1.12) 1.10 (0.92) <0.001
GFR, mil/min/1.73 m2 (SD) 76.30 (32.79) 79.73 (29.48) 72.71 (35.67) <0.001
Macrovascular disease,n (%) (1) 460 (17.4) 275 (20.2) 185 (14.4) <0.001
CHD,n (%) 329 (12.4) 197 (14.5) 132 (10.3) 0.014
Stroke,n (%) 188 (7.1) 102 (7.5) 86 (6.7) ns
Diabetic foot, n (%) (2) 100 (5.0) 48 (4.6) 52 (5.3) ns
Microvascular disease (3) 475 (32.1) 260 (34.1) 215 (30.0) ns
Albuminuria, n (%) (3) 288 (19.5) 184 (24.1) 104 (14.5) <0.001
Diabetic retinopathy, n (%) 227(15.3) 113 (14.8) 114 (16.0) ns
ACEI/ARB treatment, n (%) 1453 (54.9) 741 (54.5) 712 (55.5) ns
Calibrated Framingham cardiovascular risk
equation > 10%, n (%)
240 (9.1) 194 (14.2) 46 (3.6) <0.001
(1) Coronary heart disease (CHD) and/or stroke; (2) Ulcers and/or amputations, n = 2,000, men 1030, women 970; (3) Albuminuria and/or diabetic retinopathy,
n = 1478, men 761, women 717.
BP: blood pressure, HDL: high density lipoprotein, GFR: glomerular filtration rate, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker.
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The prevalence of different types of renal disease was:
34.1% for kidney disease, 22.9% for renal impairment,
19.5% for albuminuria and 16.4% for diabetic nephropa-
thy. Renal impairment according to the MDRD equation
was found in 606 patients (22.9%) of whom 296 (11.2%)
showed an elevated serum creatinine value (> 123.76 μmol/dl
in women and > 132.6 μmol/dl in men). Moreover, 382
patients (14.5%) showed an estimated GFR between 30 and
59 ml/min/1.73 m2, and 224 patients (8.4%) of the total
showed an estimated GFR less than 30 ml/min/1.73 m2.
Additional file 1: Table S2 shows the prevalence of kidney
disease as defined by the KDIGO workgroup [19] in 1478
T2DM patients in which the creatinine and albuminuriawas available. Among patients with RI, 71.1% were
nonalbuminuric.
There were significant differences in gender among
the forms of kidney disease. Women had a significantly
higher prevalence of kidney disease and renal impair-
ment, and men had a higher prevalence of albuminuria
and DN. Significant differences in the forms of kidney
disease were also found with the duration of diabetes
(Table 2).
Figure 2 shows that the prevalence of renal impair-
ment was similar in both sexes until age 70 and that the
prevalence of renal impairment was significantly higher
in women after age 70. In contrast, the prevalence of al-
buminuria was higher in men in all age ranges.
Table 2 Prevalence of different types of kidney disease stratified by gender and years of Type 2 diabetes duration
Total Men Women p value < 5 years diabetes duration ≥5 years diabetes duration p value
KD, n (%) (1) 505 (34.1) 235 (15.9) 270 (18.2) 0.028 327 (22.1) 178 (12.0) <0.001
RI, n (%) (2) 606 (22.9) 239 (9.0) 367 (13.9) <0.001 212 (8.0) 394 (14.9) <0.001
Diabetic nephropathy,
n (%) (1)
243 (16.4) 139 (9.4) 104 (7.0) 0.06 62 (4.2) 181 (12.2) <0.001
Albuminuria, n (%) (1) 288 (19.5) 184 (12.4) 104 (7.1) <0.001 97 (6.6) 191 (12.9) <0.001
KD: kidney disease. Albuminuria and/or altered GFR; RI: renal impairment. GFR < 60 mil/min/1.73 m2. Diabetic nephropathy: Albuminuria > 300 mg/gr or
albuminuria 30–300 mg/gr and retinopathy. Albuminuria: urinary albumin excretion rate > 30 mg/gr.
(1) n = 1478; (2) n = 2642.
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Among the 1,478 patients with T2DM who had available
data for calculating both GFR and albuminuria, patients
with albuminuria without renal impairment and no-
nalbuminuric renal impairment were compared. The
prevalence of albuminuria without renal impairment
(albuminuria alone) (13.5%) and nonalbuminuric renal
impairment (14.7%) was similar. Relative to albuminuric
patients without renal impairment, the patients with
nonalbuminuric renal impairment were significantly
older and with more probability to be women; they had a
longer T2DM duration, lower prevalence of obesity,
lower diastolic BP and lower HbA1c; and had a lower
prevalence of smoking, macrovascular disease and ische-
mic heart disease (Table 3).
Adjusted multivariate analysis shows that those T2DM
patients with renal impairment have a different profile
to those with albuminuria alone. The variables asso-
ciated with the difference between both types of KD
were: gender, years of diabetes duration and HbA1c
(Table 4). Diabetic nephropathy patients only show gen-
der differences and increased use of insulin.Figure 2 Prevalence of renal impairment and albuminuria alone stratDiscussion
Within a random sample of patients with T2DM living
in Catalonia (Spain), the prevalence of kidney disease,
renal impairment, albuminuria and diabetic nephropathy
was found to be 34.1%, 22.9%, 19.5% and 16.4%, respect-
ively. The prevalence of albuminuria without renal im-
pairment and nonalbuminuric renal impairment was
13.5% and 14.7%, respectively. In the case of renal im-
pairment, the estimation of GFR identified an additional
13.4% of patients with T2DM with renal impairment
who would not have been diagnosed only with the meas-
urement of plasma creatinine. The GFR estimation
allowed the detection of 20.6% of patients with kidney
disease in addition to the 13.5% of patients with albu-
minuria alone. When using strict criteria to define DN
[18], the prevalence decreased from 19.5% (albuminuria)
to 16.3% (albuminuria and diabetic retinopathy). Thus,
the difference between these two approaches was only
3.1%. In our study, as recommended by the NKF-K/
DOQI the same cutoff for normal AER has been used
for both sexes. In contrast, the European Societies of
Cardiology and Hypertension [20] recommend adopting°
*
*
*
ified according to age and gender (n = 806).
Table 3 Prevalence of different types of chronic kidney disease and associated variables in the 1478 diabetic patients
in wich CRI and albuminuria data were available
Albuminuria without renal impairment Nonalbuminuric renal impairment
n,(%) 200 (13.5) 217 (14.7)
Age, mean (SD) 67.49 (11.89) 72.35 (9.94)a
Gender, men (%) 137 (68.5) 75 (34.6)a
Type 2 DM duration, years (SD) 7.13 (4.89) 8.41 (6.43)a
Obesity, n (%) 75 (44.4) 79 (39.3)a
BP, mmHg (SD) 139.79/77.79 (15.22/9.35) 138.12/75.38 (14.22/8.72)b
HbA1c, mean (SD) 7.27 (1.61) 6.68 (1.42)a
Total cholesterol, mean (SD) 187.74 (37.38) 193.17 (36.66)
Non-HDL cholesterol, mg/dl, mean (SD) 141.75 (34.89) 141.81 (35.75)
Creatinine, mg/dl (SD) 0.87 (0.17) 2.38 (1.60)a
GFR, mil/min/1.73 m2 (SD) 92.49 (58.24) 36.55 (19.28)a
Tobacco, n (%) 34 (18.1) 15 (7.0)b
Macrovascular disease, n (%) 46 (23.8) 33 (15.4)a
CHD,n (%) 37 (19.2) 21 (9.8)a
Stroke, n (%) 10 (5.2) 15 (6.9)
Diabetic retinopathy, n (%) 23 (20.2) 25 (18.9)
Insulin treatment, n (%) 43 (22.0) 43 (19.9)
Calibrated Framingham CV risk eq. > 10%, n (%) 14 (10.4) 7 (6.3)
BP: blood pressure; HDL: high density lipoprotein, GFR: glomerular filtration rate, CHD: coronary heart disease, CV: cardiovascular RI: renal impairment.
Albuminuria without RI vs. Nonalbuminuric RI: a p <0.001; b p < 0.05.
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or 3.5 mg/mmol for men and <22 mg/g or 2.5 mg/mmol
for women). So, i is possible that if we had used the
European criteria, the prevalence of albuminuria would
have been similar to the prevalence obtained by [12] in a
similar cohort: 20.6%.
Previous studies have shown that renal impairment
prevalence is between 10.2 (sample of T2DM patients in
China) [21] and 36% [22] . Most studies have found a
prevalence between 15 and 30% [12-14,23-26] depending
on ethnic and demographic characteristics of the samplesTable 4 Multivariate analysis of types of kidney disease and a
Renal impairment OR (CI 95%)
Gender (men) women 2.20 (1.86–2.54)
Diabetes duration (≤10) > 10 years 1.43 (1.18–1.74)
D Diabetes duration For year 1.03 (1.02–1.05)
ACEI/ARB treatment (No) Yes 1.51 (1.27–1.79)
BP (≤ 130/80 mmHg) > 130/80 mmHg 0.86 (0.69–1.06)
HbA1c for each 1% of increase 0.85 (0.80-0.91)
Insulin treatment (No) Yes 1.82 (1.39-2.38)
Microvascular disease (No) Yes 2.14 (1.80-2.54)
In bold: p < 0.01;
Adjusted also for age, body mass index, total cholesterol and non-HDL cholesterol,
RI: renal impairment. Glomerular filtration rate < 60 mil/min/1.73 m2. Diabetic neph
retinopathy. Albuminuria: albuminuria > 30 mg/gr.; ACEI: angiotensin-converting en
glycated haemoglobin; Microvascular disease: albuminuria and/or diabetic retinopasuch as age, gender and BMI [27]. The prevalence of renal
impairment in the Mediterranean population has been
shown to be between 16.6 [12] and 31.3% [13]. These dif-
ferences may be due to younger patients and lower
percentage of women in the first study, and higher per-
centage of women in the second study. The prevalence of
albuminuria in our study (19.5%) was lower than in other
studies, ranging from 31.7 [12] to 61% [28]. This differ-
ence may be attributed to a greater number of younger
obese men. In our study, the majority (71.1%) of T2DM
patients with renal impairment had nonalbuminuric renalssociated variables in type 2 diabetic patients
Nonalbuminuric RI OR (CI 95%) Diabetic nephropathy OR (CI 95%)
0.27 (0.21–0.35) 0.56 (0.40–0.78)
0.66 (0.48–1.08) 0.80 (0.54–1.19)
0.94 (0.91–0.97) 0.97 (0.94–1.1)
1.42 (1.09–1.84) 0.98 (0.70–1.37)
2.16 (0.90–3.57) 1.18 (0.60–2.32)
1.19 (1.09-1.30) 1.21 (0.96-1.37)
1.42 (1.08-1.84) 4.17 (2.33-7.44)
- -
pulse pressure and macrovascular disease.
ropathy: albuminuria > 300 mg/gr or albuminuria 30–300 mg/gr plus
yme inhibitor; ARB: angiotensin receptor blocker; BP: blood pressure; HbA1c;
thy.
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reported prevalence [29,30]. The profile of patients with
nonalbuminuric renal impairment was different from
those with albuminuria; there was a higher proportion of
women in patients with nonalbuminuric renal impair-
ment, and these patients were older, had a higher preva-
lence of obesity, had better metabolic control with less use
of insulin, were less likely to smoke and had a lower
prevalence of macrovascular disease. These two forms of
kidney disease in patients with T2DM may correspond to
different profiles [9]. Renal impairment reflects the filtra-
tion capacity of the kidney, and albuminuria is associated
with kidney disease and generalized vascular inflamma-
tion. Renal impairment is associated with the duration of
diabetes, and albuminuria has an inverse association
where the process of glomerular involvement related to
diabetes is slower than the appearance of microalbumi-
nuria. However, both albuminuria and low GFR are inde-
pendently associated with CV morbidity, CV mortality
and total mortality [8].
The relationship between the mechanisms responsible
for the development of albuminuria and renal impairment
are not clear. In keeping with the most relevant studies
published to date, our results show that nonalbuminuric
RI is associated with female gender [9,21,25,28,29]. Nonal-
buminuric RI was associated with the time elapsed from
the diagnosis of diabetes, which was previously reported
by Retnakavaran et al. [9]. However, Penno et al. [30] re-
late the duration of diabetes to both nonalbuminuric RI
and albuminuria alone. Several authors showed that
patients with nonalbuminuric RI have lower levels of
HbA1c [9,24] and lower prevalence of obesity [28] than
those with albuminuria alone, as seen in our study.
According to our results, the profile of T2DM patient with
nonalbuminuric RI is a woman with a diagnose of diabetes
made more than 10 years ago, low percentage of obesity,
and good metabolic control measured by HbA1c. On the
other hand, the patient with albuminuria alone is prefer-
ably male, with high percentage of obesity, and poor meta-
bolic control. Diabetes duration was not significant in the
latter case. There is no obvious explanation for this phe-
nomenon other than that these diseases cause gender-
specific vascular damage. We found only one study [30]
comparing nonalbuminuric RI with albuminuria alone in
T2DM patients. Their results are in agreement with ours
in that male gender and HbA1c are associated with the
presence of albuminuria alone. However, our study showed
that the duration of diabetes and age are variables that dif-
fer in the two diseases whereas in the study of Penno et al.
[30], age and duration of diabetes, were associated with the
two forms of kidney disease. Our results may be helpful to
discriminate between these two kidney diseases by taking
into account the variables associated with each one of
them. Several studies have reported a higher prevalence ofmicrovascular damage (retinopathy and kidney disease) in
hypertensive women [31,32], but no data have been pub-
lished showing a higher prevalence of microvascular dam-
age in women with type 2 diabetes. A recent retrospective
study showed that DN appeared significantly earlier among
males than females [33]. This finding may explain the gen-
der difference we found in our cross-sectional study based
on a single observation. However, different phenotypic
expressions depending on gender cannot be excluded.
A multivariate analysis showed a clear association be-
tween renal impairment and microvascular disease. In
contrast, the bivariate analysis showed a clear association
between albuminuria and macrovascular disease al-
though the association disappeared in the multivariate
analysis. It is possible that small vessels in women are
more likely to develop damage than the small vessels in
men. If this finding is confirmed in further studies,
women with type 2 diabetes should be closely moni-
tored. Another possibility is that the glomerular filtration
rate in women estimated by the MDRD equation [34]
underestimates the GFR. Thus, the prevalence of renal
impairment would be falsely increased in women. Even
if renal function in women, is underestimated by the
MDRD equation, a recent study has reported the pre-
dictive value for coronary heart disease of the glomerular
filtration rate calculated by the MDRD equation in a co-
hort of patients with high prevalence of diabetes when is
added to the estimated risk according to Framingham
[35]. In this study, the predictive effect was independent
of albuminuria in women, but albuminuria was the vari-
able with predictive value in men.
This study had several limitations. First, in terms of in-
ternal validity, it should be noted that there was a single
measurement of GFR. Therefore, it was not possible to
distinguish between patients with transient impairment
of GFR and those with a persistent alteration. To distin-
guish between these patients, a reassessment of the GFR
at 3 months would be necessary. A previous study has
shown that kidney disease detected by a single determin-
ation is also associated with increased CV risk although
the association contributes to a lesser degree than the
two measurements [36]. Second, although the sampling
was random and well reflected the patients with type 2
diabetes treated in primary care in Catalonia (Spain), the
determination of plasma creatinine was not performed
by a single laboratory. All reference laboratories have
used Jaffé alkaline picrate method as a technique study,
the variation of which is 1.31% [37]. For this reason, we
believe that it is highly unlikely that these small differences
in the estimation of creatinine may have influenced the
results. Finally, due to the study design, patients not vis-
ited in primary care in the past year were excluded from
the study as well as patients who had no creatinine meas-
urement available during the study period. These patients
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and dyslipidaemia, which may have been caused by a
lower adherence to the prescribed treatment. Therefore,
these patients may have introduced some selection bias
into the study.
Conclusions
In summary, our results show that approximately one-
third of type 2 diabetic patients in the Mediterranean area
have kidney disease and that one-fourth of the patients
have renal impairment, but only 10% would have been
classified having renal impairment if the estimated glom-
erular filtration rate was not used. Moreover, one-fifth of
the patients had albuminuria. T2DM patients with kidney
disease have a different profile depending on the presence
or absence of albuminuria or RI. Further studies are
needed to identify the etiopathogenesis of these differ-
ences and may impact on the prevention and treatment of
forms of kidney disease. Thus, it is important to determine
AER and to estimate GFR to diagnose kidney disease and
to initiate the appropriate treatment.
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